New patents provide additional composition of
matter and methods of use claims for Enveric’s EVM301 series
neuroplastogenic molecules, and recently out-licensed
tryptamine-derived prodrugs, including EB-002, a new chemical
entity psilocin prodrug
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),
a biotechnology company dedicated to the development of novel
neuroplastogenic small-molecule therapeutics for the treatment of
anxiety, depression, and addiction disorders, today announced that
the United States Patent and Trademark Office (USPTO) has issued
two U.S. Patents, Nos. 12,133,856 (the ‘856 patent) and
12,138,276,(the ‘276 patent) bringing the total number of issued
patents supporting its EVM301 series molecules to 11. The claims of
the ‘856 patent and the ‘276 patent expand the range of protection
for novel, non-obvious multi-substituent and halogenated psilocybin
derivative compounds and pharmaceutical formulations containing
such compounds, respectively.
Enveric’s EB-003 compound emerged as Enveric’s lead candidate
from its EVM301 series of molecules and was generated from its
molecular library, Psybrary™, a proprietary catalogue of over 1,000
tryptamine derivatives that incorporates receptor engagement and
functional data to correlate structure with biological activity.
EB-003 is intended to target anxiety, depression, and addiction
disorders. Recent announcements have highlighted the promising
pre-clinical data demonstrating the potential for the EB-003
compound to promote neuroplasticity and be orally administered at
doses believed to be efficacious without hallucinogenic effect,
both of which we believe to be key criteria of commercial and
regulatory interest.
In addition, Enveric announced that the USPTO has issued two
other U.S. Patents, No. 12,065,404 (the ‘404 patent) and 12,077,498
(the ’498 patent), related to its EVM201 series prodrug molecules.
The claims of the ‘404 patent and ‘498 patent protect novel,
non-obvious C4-carboxylic acid-substituted tryptamine derivative
compounds and pharmaceutical drug formulations containing such
compounds, and methods of making such compounds, respectively.
These compounds are prodrugs intended to treat neurological
disorders. Enveric recently announced that it licensed its EVM201
Series to MycoMedica Life Sciences (MycoMedica). These additional
patents strengthen and underscore the potential value to Enveric
and MycoMedica, which plans to develop the lead EVM201 Series
compound EB-002.
“These patent issuances from the USPTO add important pillars to
Enveric’s intellectual property portfolio as we continue to
distinguish the pre-clinical performance of our tryptamine-based
molecules under development for the treatment of mental health
disorders from others on the market or under development,” said
Joseph Tucker, Ph.D., Director and CEO of Enveric. “Importantly,
with our focus squarely on our EVM301 Series, we expect to continue
uncovering positive data highlighting the promising properties of
EB-003, which is designed to capitalize on the potential for
inducing neuroplasticity without causing hallucinations that can
meet key commercial and regulatory criteria to advance to clinical
trials.”
Enveric has announced out-licensing deals with MycoMedica and
Aries Science & Technology, which positions Enveric to focus
its resources on development of its lead compound EB-003. These
deals establish potential future income streams to support the
development and commercialization of Enveric’s pipeline
candidates.
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company
dedicated to the development of novel neuroplastogenic
small-molecule therapeutics for the treatment of depression,
anxiety, and addiction disorders. Leveraging its unique discovery
and development platform, Psybrary™, Enveric has created a robust
intellectual property portfolio of new chemical entities for
specific mental health indications. Enveric’s lead molecule,
EB-003, is a potential first-in-class neuroplastogen designed to
promote neuroplasticity, without inducing hallucinations, in
patients suffering from difficult-to-address mental health
disorders. Enveric is focused on advancing EB-003 towards clinical
trials for the treatment of neuropsychiatric disorders while
out-licensing all other novel, patented Psybrary™ drug candidates
to third-party licensees advancing non-competitive market
strategies for patient care. Enveric is headquartered in Naples, FL
with offices in Cambridge, MA and Calgary, AB Canada. For more
information, please visit www.enveric.com.
Forward-Looking Statements
This press release contains forward-looking statements and
forward-looking information within the meaning of applicable
securities laws. These statements relate to future events or future
performance. All statements other than statements of historical
fact may be forward-looking statements or information. Generally,
forward-looking statements and information may be identified by the
use of forward-looking terminology such as “plans,” “expects” or
“does not expect,” “proposes,” “budgets,” “explores,” “schedules,”
“seeks,” “estimates,” “forecasts,” “intends,” “anticipates” or
“does not anticipate,” or “believes,” or variations of such words
and phrases, or by the use of words or phrases which state that
certain actions, events or results may, could, should, would, or
might occur or be achieved. Forward-looking statements may include
statements regarding beliefs, plans, expectations, or intentions
regarding the future and are based on the beliefs of management as
well as assumptions made by and information currently available to
management. Actual results could differ materially from those
contemplated by the forward-looking statements as a result of
certain factors, including, but not limited to, the ability of
Enveric to: successfully outlicense patented Psybrary™ drug
candidates to third-party licensees; negotiate and finalize
definitive agreements based on any of its out-licensing term sheets
and for licensees to perform pursuant to the terms thereof;
finalize and submit its IND filing to the U.S. Food and Drug
Administration; carry out successful clinical programs; achieve the
value creation contemplated by technical developments; avoid delays
in planned clinical trials; establish that potential products are
efficacious or safe in preclinical or clinical trials; establish or
maintain collaborations for the development of therapeutic
candidates; obtain appropriate or necessary governmental approvals
to market potential products; obtain future funding for product
development and working capital on commercially reasonable terms;
scale-up manufacture of product candidates; respond to changes in
the size and nature of competitors; hire and retain key executives
and scientists; secure and enforce legal rights related to
Enveric’s products, including patent protection; identify and
pursue alternative routes to capture value from its research and
development pipeline assets; continue as a going concern; and
manage its future growth effectively.
A discussion of these and other factors, including risks and
uncertainties with respect to Enveric, is set forth in Enveric’s
filings with the Securities and Exchange Commission, including
Enveric’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Enveric disclaims any intention or obligation to revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241202968398/en/
Investor Relations Tiberend Strategic Advisors, Inc. David Irish
(231) 632-0002 dirish@tiberend.com
Media Relations Tiberend Strategic Advisors, Inc. Casey McDonald
(646) 577-8520 cmcdonald@tiberend.com
Enveric Biosciences (NASDAQ:ENVB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Enveric Biosciences (NASDAQ:ENVB)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
